{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T17:08:51Z","timestamp":1792516131410,"version":"4.5.0"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002701","name":"Ministry of Education","doi-asserted-by":"publisher","award":["NRF-2022R1C1C1005415"],"award-info":[{"award-number":["NRF-2022R1C1C1005415"]}],"id":[{"id":"10.13039\/501100002701","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thegreenjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Radiotherapy and Oncology"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.radonc.2022.09.003","type":"journal-article","created":{"date-parts":[[2022,9,14]],"date-time":"2022-09-14T06:54:43Z","timestamp":1663138483000},"page":"9-16","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["A phase II trial of hypofractionated high-dose proton beam therapy for unresectable liver metastases"],"prefix":"10.1016","volume":"176","author":[{"given":"Kangpyo","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeong Il","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hee Chul","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gyu Sang","family":"Yoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Do Hoon","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae Myoung","family":"Noh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Woo Kyoung","family":"Jeong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.radonc.2022.09.003_b0005","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1245\/s10434-013-3297-7","article-title":"Cause of death from liver metastases in colorectal cancer","volume":"21","author":"Helling","year":"2014","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.radonc.2022.09.003_b0010","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.radonc.2015.09.011","article-title":"Proton beam therapy for metastatic liver tumors","volume":"117","author":"Fukumitsu","year":"2015","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2022.09.003_b0015","doi-asserted-by":"crossref","first-page":"29765","DOI":"10.1038\/srep29765","article-title":"Patterns of metastasis in colon and rectal cancer","volume":"6","author":"Riihimaki","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.radonc.2022.09.003_b0020","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/j.jamcollsurg.2009.12.041","article-title":"Conditional survival after surgical resection of colorectal liver metastasis: an international multi-institutional analysis of 949 patients","volume":"210","author":"Nathan","year":"2010","journal-title":"J Am Coll Surg"},{"key":"10.1016\/j.radonc.2022.09.003_b0025","doi-asserted-by":"crossref","first-page":"4575","DOI":"10.1200\/JCO.2007.11.0833","article-title":"Actual 10-year survival after resection of colorectal liver Metastases defines cure","volume":"25","author":"Tomlinson","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2022.09.003_b0030","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.1245\/s10434-008-9935-9","article-title":"Liver surgery for colorectal metastases: results after 10 years of follow-up. Long-term survivors, late recurrences, and prognostic role of morbidity","volume":"15","author":"Vigano","year":"2008","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.radonc.2022.09.003_b0035","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1007\/s00330-008-1258-5","article-title":"Five-year survival in 309 patients with colorectal liver metastases treated with radiofrequency ablation","volume":"19","author":"Gillams","year":"2009","journal-title":"Eur Radiol"},{"key":"10.1016\/j.radonc.2022.09.003_b0040","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1200\/JCO.2001.19.1.164","article-title":"Stereotactic single-dose radiation therapy of liver tumors: results of a phase I\/II trial","volume":"19","author":"Herfarth","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2022.09.003_b0045","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1200\/JCO.2008.20.0600","article-title":"Phase I study of individualized stereotactic body radiotherapy of liver metastases","volume":"27","author":"Lee","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2022.09.003_b0050","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1097\/SLA.0b013e318155a7b6","article-title":"Survival after radiofrequency ablation of colorectal liver metastases: 10-year experience","volume":"246","author":"Siperstein","year":"2007","journal-title":"Ann Surg"},{"key":"10.1016\/j.radonc.2022.09.003_b0055","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1111\/hpb.12181","article-title":"Outcomes of extended versus limited indications for patients undergoing a liver resection for colorectal cancer liver metastases","volume":"16","author":"van Dam","year":"2014","journal-title":"HPB (Oxford)"},{"key":"10.1016\/j.radonc.2022.09.003_b0060","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.radonc.2014.11.033","article-title":"Charged particle therapy versus photon therapy for patients with hepatocellular carcinoma: a systematic review and meta-analysis","volume":"114","author":"Qi","year":"2015","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2022.09.003_b0065","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.ijrobp.2017.12.288","article-title":"Local control after stereotactic body radiation therapy for liver tumors","volume":"110","author":"Ohri","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2022.09.003_b0070","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/S0360-3016(02)02846-8","article-title":"Analysis of radiation-induced liver disease using the Lyman NTCP model","volume":"53","author":"Dawson","year":"2002","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2022.09.003_b0075","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.ijrobp.2006.08.015","article-title":"Dose-volumetric parameters predicting radiation-induced hepatic toxicity in unresectable hepatocellular carcinoma patients treated with three-dimensional conformal radiotherapy","volume":"67","author":"Kim","year":"2007","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2022.09.003_b0080","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1177\/030089161309900208","article-title":"Predictive factors for Child-Pugh score elevation in hepatocellular carcinoma patients treated with conformal radiation therapy: dose-volume histogram analysis","volume":"99","author":"Yu","year":"2013","journal-title":"Tumori"},{"key":"10.1016\/j.radonc.2022.09.003_b0085","doi-asserted-by":"crossref","first-page":"3053","DOI":"10.1002\/cncr.25809","article-title":"The safety and efficacy of high-dose proton beam radiotherapy for hepatocellular carcinoma: a phase 2 prospective trial","volume":"117","author":"Bush","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.radonc.2022.09.003_b0090","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.jhep.2020.09.026","article-title":"Proton beam radiotherapy vs. radiofrequency ablation for recurrent hepatocellular carcinoma: A randomized phase III trial","volume":"74","author":"Kim","year":"2021","journal-title":"J Hepatol"},{"key":"10.1016\/j.radonc.2022.09.003_b0095","doi-asserted-by":"crossref","first-page":"25","DOI":"10.3857\/roj.2017.00409","article-title":"Initial clinical outcomes of proton beam radiotherapy for hepatocellular carcinoma","volume":"36","author":"Yu","year":"2018","journal-title":"Radiat Oncol J"},{"key":"10.1016\/j.radonc.2022.09.003_b0100","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1200\/JCO.2014.57.9151","article-title":"Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade","volume":"33","author":"Johnson","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2022.09.003_b0105","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.radonc.2022.09.003_b0110","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.radonc.2020.02.019","article-title":"Comparison of clinical outcomes between passive scattering versus pencil -beam scanning proton beam therapy for hepatocellular carcinoma","volume":"146","author":"Yoo","year":"2020","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2022.09.003_b0115","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1016\/S1470-2045(19)30718-1","article-title":"Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation","volume":"21","author":"Guckenberger","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2022.09.003_b0120","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1200\/JCO.2015.61.4925","article-title":"Outcomes after stereotactic body radiotherapy or radiofrequency ablation for hepatocellular Carcinoma","volume":"34","author":"Wahl","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2022.09.003_b0125","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.jhep.2020.03.005","article-title":"Stereotactic body radiation therapy vs. radiofrequency ablation in Asian patients with hepatocellular carcinoma","volume":"73","author":"Kim","year":"2020","journal-title":"J Hepatol"},{"key":"10.1016\/j.radonc.2022.09.003_b0130","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1111\/jgh.15442","article-title":"Radiofrequency ablation versus stereotactic body radiation therapy for small (<\/= 3 cm) hepatocellular carcinoma: A retrospective comparison analysis","volume":"36","author":"Jeong","year":"2021","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.radonc.2022.09.003_b0135","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1200\/JCO.2008.19.6329","article-title":"Multi-institutional phase I\/II trial of stereotactic body radiation therapy for liver metastases","volume":"27","author":"Rusthoven","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2022.09.003_b0140","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s13014-018-0969-2","article-title":"Stereotactic Body Radiotherapy (SBRT) for liver metastasis - clinical outcomes from the international multi-institutional RSSearch(R) Patient Registry","volume":"13","author":"Mahadevan","year":"2018","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.radonc.2022.09.003_b0145","first-page":"45","article-title":"High versus low dose Stereotactic Body Radiation Therapy for hepatic metastases","volume":"20","author":"Kok","year":"2020","journal-title":"Clin Transl Radiat Oncol"},{"key":"10.1016\/j.radonc.2022.09.003_b0150","doi-asserted-by":"crossref","first-page":"783327","DOI":"10.3389\/fonc.2021.783327","article-title":"Clinical effectiveness of hypofractionated proton beam therapy for liver metastasis from breast cancer","volume":"11","author":"Kim","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.radonc.2022.09.003_b0155","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.21037\/jgo-20-424","article-title":"Proton stereotactic body radiation therapy for liver metastases-results of 5-year experience for 81 hepatic lesions","volume":"12","author":"Coffman","year":"2021","journal-title":"J Gastrointest Oncol"},{"key":"10.1016\/j.radonc.2022.09.003_b0160","doi-asserted-by":"crossref","first-page":"djx031","DOI":"10.1093\/jnci\/djx031","article-title":"Phase II study of proton-based stereotactic body radiation therapy for liver metastases: Importance of tumor genotype","volume":"109","author":"Hong","year":"2017","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.radonc.2022.09.003_b0165","doi-asserted-by":"crossref","first-page":"112","DOI":"10.21037\/jgo.2018.08.17","article-title":"A phase I trial of Proton stereotactic body radiation therapy for liver metastases","volume":"10","author":"Kang","year":"2019","journal-title":"J Gastrointest Oncol"},{"key":"10.1016\/j.radonc.2022.09.003_b0170","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1186\/s13014-015-0428-2","article-title":"Microinvasion of liver metastases from colorectal cancer: predictive factors and application for determining clinical target volume","volume":"10","author":"Qian","year":"2015","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.radonc.2022.09.003_b0175","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1593\/neo.06823","article-title":"Oncogenic K-Ras signals through epidermal growth factor receptor and wild-type H-Ras to promote radiation survival in pancreatic and colorectal carcinoma cells","volume":"9","author":"Cengel","year":"2007","journal-title":"Neoplasia"},{"key":"10.1016\/j.radonc.2022.09.003_b0180","doi-asserted-by":"crossref","first-page":"12153","DOI":"10.3390\/ijms131012153","article-title":"Prognostic and predictive roles of KRAS mutation in colorectal cancer","volume":"13","author":"Arrington","year":"2012","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.radonc.2022.09.003_b0185","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.radonc.2020.02.008","article-title":"Association of tumor genomic factors and efficacy for metastasis-directed stereotactic body radiotherapy for oligometastatic colorectal cancer","volume":"146","author":"Jethwa","year":"2020","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2022.09.003_b0190","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1080\/02656736.2018.1556818","article-title":"The value of KRAS gene status in predicting local tumor progression of colorectal liver metastases following radiofrequency ablation","volume":"36","author":"Jiang","year":"2019","journal-title":"Int J Hyperthermia"}],"container-title":["Radiotherapy and Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814022042670?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814022042670?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T05:21:54Z","timestamp":1759123314000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167814022042670"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":38,"alternative-id":["S0167814022042670"],"URL":"https:\/\/doi.org\/10.1016\/j.radonc.2022.09.003","relation":{},"ISSN":["0167-8140"],"issn-type":[{"value":"0167-8140","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A phase II trial of hypofractionated high-dose proton beam therapy for unresectable liver metastases","name":"articletitle","label":"Article Title"},{"value":"Radiotherapy and Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.radonc.2022.09.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}